Liver cell protection against apoptosis

This term describes the set of molecular mechanisms and pathways that prevent apoptosis (programmed cell death) in liver cells (hepatocytes). Protective mechanisms encompass upregulation of anti-apoptotic Bcl-2 family proteins (such as Bcl-2, Bcl-xL, and Mcl-1), inhibition of death receptor pathways (such as Fas and TNF-R1/TNF-α), attenuation of mitochondrial outer membrane permeabilization, activation of survival signaling (for example via NF-κB from TNF-α), reduction of oxidative and endoplasmic reticulum stress, and promotion of autophagy to remove damaged cellular components. Failure of these protective mechanisms contributes to acute and chronic liver diseases, including hepatitis, fibrosis, cirrhosis, and cancer. Numerous drugs and experimental agents target specific molecular participants within these pathways to enhance hepatocyte survival or reduce inappropriate apoptosis. "Liver cell protection against apoptosis" is not a canonical molecular target, but an umbrella process involving many molecular targets (such as Bcl-2 family proteins, mitochondrial channels, caspases, death receptors), each of which can be considered a true drug target individually.

Other names

Hepatocyte anti-apoptosisLiver cell survival pathwaysLiver anti-apoptotic mechanisms

This term refers to a complex interplay of various molecular mechanisms that prevent hepatocyte apoptosis. These mechanisms include, but are not limited to, the upregulation of anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL), inhibition of pro-apoptotic factors (e.g., caspases), modulation of death receptor signaling (e.g., Fas, TNF-R1), reduction of mitochondrial outer membrane permeabilization, activation of survival signaling pathways (e.g., NF-κB), and mitigation of cellular stresses (oxidative, ER stress). These are not a single mechanism for a singular target, but rather a collective description of how the liver maintains cell viability.